Blog example
Nicky Veringmeier
Marketing
Your content goes here. Edit or remove this text inline or in the module Content settings.
You can also style every aspect of this content in the module Design settings and even apply custom CSS to this text in the module Advanced settings.
The multi-product facility is designed to support the late-stage clinical manufacturing and commercial manufacturing of vaccines and viral vector-based gene therapy and immune-oncology products.
Batavia’s highly intensified manufacturing technology, HIP-Vax®, which utilizes fixed-bed bioreactors, will be the main platform, but also products manufactured using traditional mammalian cell suspension technologies up to 1000L scale can readily be delivered. The facility is based on a modular design, with 6 production suites. On-site, state-of-the-art fill / finish capabilities ensure on-time delivery of drug product. Depending on virus / vector type the facility is expected to provide for several hundred million doses annually.
Related
Protected: Expertise Questionnaire
Password Protected
To view this protected post, enter the password below:
Pablo Mendes de León
CFO Pablo Mendes de León is a member of the Management Team of Batavia Biosciences. Pablo joined Batavia in November 2018. Before joining our company he held several senior positions within the real estate industry. Prior to this he worked as financial controller and...
Jolanda van Vliet
Director QA & QP Jolanda van Vliet is a member of the Management Team of Batavia Biosciences. Jolanda joined Batavia Biosciences in March 2013 and assumes the position as Director Quality Assurance (QA) and Qualified Person (QP). Before joining Batavia...
Your content goes here. Edit or remove this text inline or in the module Content settings. You can also style every aspect of this content in the module Design settings and even apply custom CSS to this text in the module Advanced settings.
